The Food and Drug Administration announced Tuesday that it is developing a framework for regulating artificial intelligence products used in medicine that continually adapt based on new data.

The agency’s outgoing commissioner, Scott Gottlieb, released a white paper that sets forth the broad outlines of the FDA’s proposed approach to establishing greater oversight over this rapidly evolving segment of AI products.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi!
    Good article, I opine that as AI-related systems will have a constant change with exposure to Data and their outcomes, so locked strategy will lead to immediate go to market strategy. But in Locked Strategy the difficulty is many AI software companies they validate their Algorithms on a specific vendors data, and they get approvals based on that specific vendor data, and they cant claim they can universally use the same algorithm for other vendor data. For example fundus camera for DR screening – Different Fundus Cameras will give different resolution and different color patterns, its important to understand that the AI companies have checked and thoroughly validated on all vendors data before they get into locked strategy….

  • While there are risks of rapidly evolving digital technology, they likely will be overweighed by immense benefits to population health and personalized medical care. The public policy challenge is how to allow and encourage innovation without stifling it, and striking an acceptable balance.

    Autonomous learning and self-correction allow for improvements at a much faster pace than could ever be done by human engineering and FDA approval processes. With that said, I think we need ways to know the reasoning behind those changes so we humans learn from the machines.

  • “So our paper also takes on one of the key barriers for AI in clinical practice: the “black box” problem. For most AI systems, it’s very hard to understand exactly why they make a recommendation. That’s a huge issue for clinicians and patients who need to understand the system’s reasoning, not just its output – the why as well as the what.
    Our system takes a novel approach to this problem, combining two different neural networks …”
    https://deepmind.com/blog/moorfields-major-milestone/

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy